title: [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
abstract: The authors have obtained a panel of 7 monoclonal antibodies (MAbs) against pandemic influenza virus A/IIV-Moscow/01/2009 (HIN1)swl isolated in Russia. One MAb is directed to a NP protein linear epitope and interacts with all the influenza A viruses under study. Six other MAbs are directed to H1 hemagglutinin conformation-dependent determinants and detect homologous virus in the hemagglutination-inhibition test, enzyme immunoassay, immunofluorescence and virus neutralization tests. MAbs differentiate pandemic influenza viruses A(H1N1)swl from seasonal influenza A(H1N1), A(H3N2), and B viruses. The high neutralizing activity of MAbs permits their use to study the fine antigen structure of influenza virus hemagglutinin and to differentiate the A(H1N1) pandemic influenza viruses and offers promise for obtaining humanized antibodies in order to make specific prevention and treatment of influenza.
authors.forename: R R
authors.initials: RR
authors.lastname: Klimova
authors.forename: O V
authors.initials: OV
authors.lastname: Masalova
authors.forename: E I
authors.initials: EI
authors.lastname: Burtseva
authors.forename: E V
authors.initials: EV
authors.lastname: Chichev
authors.forename: E I
authors.initials: EI
authors.lastname: Lesnova
authors.forename: T A
authors.initials: TA
authors.lastname: Oskerko
authors.forename: E A
authors.initials: EA
authors.lastname: Mukasheva
authors.forename: I A
authors.initials: IA
authors.lastname: Rudneva
authors.forename: D K
authors.initials: DK
authors.lastname: Lvov
authors.forename: A A
authors.initials: AA
authors.lastname: Kushch
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000302:isolation & purification*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000302:isolation & purification*; D000914:Antibodies, Viral / Q000276:immunology / Q000302:isolation & purification*; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D053118:Influenza A Virus, H1N1 Subtype / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology; D007251:Influenza, Human / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008968:Molecular Conformation; D009031:Moscow; D009500:Neutralization Tests; D058873:Pandemics
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; C483468:hemagglutinin, human influenza A virus